Register
FDA approves triclabendazole for fascioliasis |
News and Updates
eMediNexus Coverage from: 
FDA approves triclabendazole for fascioliasis

1 Read Comments                

The US Food and Drug Administration (FDA) has approved triclabendazole (Egaten, Novartis) to treat fascioliasis a neglected tropical disease, in patients aged 6 years or older. Fascioliasis or liver fluke infestation is a waterborne and food-borne zoonotic disease caused by two species of parasitic flatworms.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now